
-
Djokovic stays on track for Wimbledon glory under Federer gaze
-
Belgian Merlier wins crash-marred Tour de France stage
-
Djokovic battles back against De Minaur to stay on track for Wimbledon glory
-
Israel, Hamas hold indirect talks ahead of Netanyahu-Trump meet
-
Trump steps up pressure for deals as US tariff deadline nears
-
Iran president says Israel attempted to assassinate him
-
Russia says minister fired by Putin killed himself
-
Ex-All Black Nonu extends Toulon deal, aged 43
-
Stocks diverge as US tariff deadline looms
-
French court dismisses government Covid response probe
-
Children's camp confirms 27 dead, with Texas flood toll over 80
-
BRICS' criticism brings Trump 10% tariff threat
-
Houses made from rice: Kyrgyzstan's eco-friendly revolution
-
Croatia govt lashed over 'disgraceful neo-fascist Woodstock'
-
Victims of London 7/7 attacks remembered as king hails 'spirit of unity'
-
Poland starts border checks with Germany in anti-migrant clampdown
-
Wiaan Mulder: slow ascent to Test cricket's batting heights
-
England coach McCullum says paceman Archer 'ready to go' against India
-
Djokovic, Sinner on Wimbledon collision course
-
Vaughan says Crawley 'lucky' to have so many England caps
-
Russian forces claim first foothold in new Ukraine region
-
US envoy says satisfied with Lebanese response on disarming of Hezbollah
-
European stocks, dollar firm as US tariff deadline looms
-
Wimbledon blames 'human error' for embarrassing line-calling glitch
-
Three things learned from British Grand Prix
-
NGOs laud tougher Malaysia plastic trash import laws
-
Mulder makes highest South Africa Test score
-
UK marks London 7/7 attacks as king hails 'spirit of unity'
-
Apple appeals 500-mn-euro EU fine
-
Crowds celebrate Nepal ex-king's birthday in show of support
-
Bali flights nixed after huge Indonesia volcano eruption
-
Hamas, Israel resume talks as Netanyahu set to meet Trump
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM
-
North Korea bars Western influencers from trade fair tour
-
Typhoon Danas kills two, injures hundreds in Taiwan
-
Dutch coastal village turns to tech to find lost fishermen
-
Boxer Chavez's appeal against arrest if deported from US rejected: Mexico prosecutor
-
India captain Gill hailed back home after 'brilliant' Test win
-
The making of Australia's mushroom murders
-
Indonesia volcano spews 18-kilometre ash tower
-
Youthful Chelsea ready for Thiago Silva reunion at Club World Cup
-
Australian inquiry cites racism in Indigenous shooting
-
Djokovic wary despite Wimbledon form, dominant Sinner faces Dimitrov
-
Australian woman found guilty of triple murder with toxic mushrooms
-
Indonesia volcano spews 18-kilometre ash tower: agency
-
Trump says to send first tariff letters on Monday
-
The strange case of Evgeniya Mayboroda, Russia's rebel retiree

US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
D.Sawyer--AMWN